Liver function testing in patients on HMG-CoA reductase inhibitors

Area of Science:

• Pharmacovigilance
• Clinical Practice Guidelines
• Hepatology

Background:

• The U.S. Food and Drug Administration mandates liver function tests (LFTs) for patients initiating HMG-CoA reductase inhibitor therapy.
• Guidelines recommend baseline and periodic LFT monitoring, varying by specific HMG-CoA reductase inhibitor agent.
• Understanding real-world LFT screening practices is crucial for patient safety and guideline adherence.

Purpose of the Study:

• To investigate the frequency and patterns of LFT screening in patients prescribed HMG-CoA reductase inhibitors.
• To assess adherence to recommended LFT monitoring protocols in a managed care population.
• To identify the incidence of LFT abnormalities in users of these lipid-lowering agents.

Main Methods:

• A retrospective cohort study analyzed 4178 new users of HMG-CoA reductase inhibitors from 1991 to 1996.
• Data included LFT screening within 180 days pre-dispensing (baseline) and post-dispensing (follow-up).
• Proportions of therapy courses with LFTs and incidence of LFT abnormalities were calculated.

Main Results:

• 47% of patients had baseline LFTs, and 73% had follow-up LFTs for their initial HMG-CoA reductase inhibitor prescription.
• A small fraction (0.9%) of patients with follow-up LFTs exhibited levels exceeding three times the upper limit of normal.
• In a sample of discontinued patients, none ceased therapy due to elevated LFTs or liver disease.

Conclusions:

• A significant proportion of patients receiving HMG-CoA reductase inhibitors in this managed care setting did not undergo recommended baseline and follow-up LFTs.
• While minor LFT elevations were observed, severe abnormalities and treatment discontinuation due to liver issues were infrequent.
• Findings suggest a gap in adherence to LFT monitoring guidelines for HMG-CoA reductase inhibitors in this population.